Dr. Toole joined Gilead in 1990 and held the role of Senior Vice President, Clinical Research
from 2001-2008. He was also responsible for setting the strategy for and managing
the company's business development and alliance management activities from
2008-2011. Prior to joining Gilead, he was a founding researcher of Genetics
Institute, Inc. in Cambridge, Massachusetts. He also completed postdoctoral fellowships
at Harvard Medical School and the Massachusetts Institute of Technology.
Dr. Toole received his MD from Stanford University School of Medicine and his PhD from the State University of New York at Buffalo.

Dr. Marquez received his Ph.D. in Medicinal Chemistry from the University of Michigan in 1970. After 1 year of postdoctoral training at the NCI, he worked in private industry for 5 years in Venezuela. He rejoined the NCI in 1977 as a Visiting Scientist, was awarded tenure as a Principle Investigator in 1987 after becoming a naturalized citizen, and then promoted to Lab Chief in 2001. His main research interests are nucleoside chemistry and synthetic organic chemistry as tools for the rational design of antitumor and antiviral agents. Dr. Marquez has authored or coauthored more than 310 publications and has received 25 U.S. patents. Dr. Marquez retired as Lab Chief on September 30, 2009 and is now Scientist Emeritus.

Dr. M.C. Kang has experience in new drug discovery at Global Pharmaceutical and Venture companies. He is developed and released Fuzeon of AIDS drug as Chief vice president in Trimeris of Venture Company in the United States (1995-2003). He had an experience for successful IPO in NASQ. Dr. M.C. kang earned his Ph.D. in organic chemistry at Oregon University after receiving B.S. in Chemistry at Sogang University in 1975. After a postdoctoral fellowship at Harvard University, he worked in GSK as a Director in Medicinal Chemistry.

Stephen Frye is the Director of the Center for Integrative Chemical Biology and Drug Discovery and a Research Professor within the Medicinal Chemistry and Natural Products Division in the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. Stephen was previously the World-wide Vice President of Discovery Medicinal Chemistry at GlaxoSmithKline where he directed all hit to lead discovery activities for the company. While at GSK, Stephen invented Avodart, a dual 5 alpha-reductase inhibitor marketed to treat prostatic disease. He also created a global kinase chemistry team that discovered Tykerb (metastatic breast cancer) and Pazopanib (renal carcinoma). He received his Ph.D. in organic chemistry from the University of North Carolina in 1987. Stephen has more than 50 patents and publications.

Dr. Carrolee Barlow is a world-renowned neurodegeneration expert, working as the CEO of Parkinson Research Center in California. Dr. Barlow is an expert in patient treatment, fundamental research and clinical trials; she was once a professor at Salk Institute for Biological Studies. Afterwards, she was Director and Manager of the Neuroscience department at Merck. Dr. Barlow received a Doctorate degree on molecular gerontology from Karolinska Medical Nobel Institute in Sweden, a medical Doctor degree From Utah University, and finished her residency at Cornell Medical Center.

Professor Kim Eunhee is a Biology professor at the Graduate School of Drug Development in Chung Nam University. She uncovered the α-synuclein Mechanism behind the relationship between FAF1 and Parkinson’s disease, and proved the effectiveness of KM-819 through various cell and animal models. She graduated from Seoul National University with a degree in microorganism and she received a doctorate degree on molecular gerontology from Tufts University. Afterwards, she worked at the Korea Chemistry Research Institute and BaeJae University. She was also the chief editor, chief of Fusion Science and the chief of international cooperation department of the Korean Society for Molecular and Cellular Biology; Her research focuses on cell death, Parkinson disease and medicine in macular degeneration.

Professor Lee Jong Sik is a professor at the Seoul Asan Medical Center and an expert in Parkinson’s disease and abnormal motor diseases. He interned in and graduated from the Seoul National University Medical School, and he studied at the University of British Columbia for the next four years in Neuroscience. Afterwards, professor Lee studied University of British Columbia’s Neurodegenerative Disorders Studies, worked as a researcher at Lund University and Wallenberg Neuroscience Center, and then worked as assistant professor in Univ. of British Columbia, Neurology & Pacific Parkinson’s Research Center.